It been a while since Anteris advised the market on internal NPV calculations. With the advances made since then there must be a reasonable reduction in risk metrics. It will be very interesting to hear there next valuation.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-2
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.29 |
Change
-0.010(0.05%) |
Mkt cap ! $408.9M | |||
| Open | High | Low | Value | Volume |
| $21.70 | $21.70 | $21.16 | $147.0K | 6.914K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47 | $21.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.60 | 300 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.19 |
Change
-0.010 ( 0.47 %) |
||||
| Open | High | Low | Volume | ||
| $21.69 | $21.70 | $21.19 | 122 | ||
| Last updated 13.18pm 03/05/2024 ? | |||||
| AVR (ASX) Chart |